<![CDATA[Pembrolizumab/Denosumab Combo Shows Activity in Pretreated ccRCC]]>

Phase 2positivePembrolizumabDenosumabPositive

AI Analysis

Summary

A phase 2 trial showed that the combination of pembrolizumab and denosumab achieved a 31% objective response rate in patients with pretreated advanced clear cell renal cell carcinoma, demonstrating therapeutic activity in this resistant patient population.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

31% objective response rate in pretreated advanced ccRCC

Importance:6/10

Sentiment:

0.65

oncologyimmunotherapyrenal cell carcinomacombination therapycheckpoint inhibitor

Related Companies

$MRK $AMGN

Read the original article

Published by Cancer Network on August 19, 2026 4:00 PM

Read Original